Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Sun Pharma Q4 profit...

    Sun Pharma Q4 profit falls by half to Rs 636 crore due to change in distribution strategy

    GarimaWritten by Garima Published On 2019-05-29T09:45:04+05:30  |  Updated On 13 Aug 2021 4:48 PM IST

    Sun Pharma said the net profit for the fourth quarter of FY2018-19 is not comparable with the year-ago period due to the one-time impact of distribution change for India business in the fourth quarter of 2018-19 as well as the one-time tax benefit of Rs 259 crore for the same quarter during the last year.


    New Delhi: Drug major Sun Pharmaceutical Industries Tuesday reported a consolidated net profit of Rs 635.88 crore for the fourth quarter ended on March 31, 2019.


    The company had posted a net profit of Rs 1,342.50 crore for the corresponding period of the previous fiscal, Sun Pharmaceutical Industries said in a filing to BSE.










    The profit was mainly impacted by distribution change for its India business.


    Read Also: Dilip Shanghvi plans comeback; Sun Pharma to develop its own medicines: Report








    The company said the net profit for the fourth quarter of FY2018-19 is not comparable with the year-ago period due to the one-time impact of distribution change for India business in the fourth quarter of 2018-19 as well as the one-time tax benefit of Rs 259 crore for the same quarter during the last year.


    Earlier in April this year, Sun Pharma had said that the transition of distribution related to India domestic formulations business from Aditya Medisales to company's arm Sun Pharma Distributors will impact the financial results for the period ended March 31, 2019.


    Consolidated revenue from operations of the company stood at Rs 7,044.26 crore for the quarter under consideration. It was Rs 6,711.01 crore for the same period a year ago.


    "Sales for the quarter include a one-time impact of approximately Rs 1,085 crore related to the change in distribution for India business," Sun Pharma said.


    Sale of branded formulations in India for the last quarter of 2018-19 was Rs 1,101 crore, down by 44 per cent, the company said.


    Read Also: Sun Pharma submits proposal to CDSCO for manufacturing, marketing FDC to treat URTI; Details


    However, sales in the US were $443 million (around Rs 3,082 crore) for the quarter, a growth of 20 per cent over the same period last year and accounted for 44 per cent of total sales, it added.


    For the fiscal year ended March this year, the net profit of the company stood at Rs 2,665.42 crore. It was Rs 2,095.70 crore for the previous fiscal year.


    Consolidated revenue from operations of the company stood at Rs 28,686.28 crore for the fiscal year ended March 2019. It was Rs 26,065.94 crore for the year-ago fiscal year.


    Commenting on the results, Sun Pharma Managing Director Dilip Shanghvi said, "In spite of the one-time impact for India business, our full-year sales have grown by double digits." The company continues to focus on executing its global speciality strategy. Ilumya is expected to gradually gain traction in the US in FY2019-20 while Cequa launch is expected in the coming months, he added.


    "At the same time, we are strengthening our core operations, optimising the cost structure and enhancing our overall efficiencies," Shanghvi said.


    For 2019-20 fiscal, the company has earmarked a capital expenditure of USD 200 million (Rs 1,391 crore), Shanghvi said during an earnings call.


    Sun Pharma said its board has recommended payment of a dividend of Rs 2.75 per equity share of Re 1 each for the year ended March 31, 2019.

    Aditya MedisalesBSEconsolidated revenueDilip Shanghvidistribution for india bizFY 2019IndiarevenueShares of Sun PharmaceuticalSun Pharmasun pharma distributorssun pharma dividendsun pharma fourth quartersun pharma half profitSun Pharmaceutical Industriestax benefitsUnited States
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok